Nucor earnings beat by $0.08, revenue fell short of estimates
In a challenging market environment, Harte Hanks Inc. (NASDAQ:HHS) stock has touched a 52-week low, dipping to $4.24. According to InvestingPro analysis, the stock appears undervalued at current levels, with analysts setting an ambitious target of $17.50. The marketing services company has faced significant headwinds over the past year, reflected in the stock’s performance with a 1-year change showing a steep decline of -38.74%. Investors have been cautious as the company navigates through a period of uncertainty, with a negative EBITDA of $28.35M in the last twelve months. However, the company maintains a healthy current ratio of 1.49, and its beta of -0.15 suggests it could serve as a market hedge. The current price level marks a critical point for Harte Hanks as it attempts to stabilize and attract investor confidence in the face of ongoing market volatility. For deeper insights into HHS’s valuation and future prospects, explore the comprehensive Pro Research Report available on InvestingPro, which covers over 1,400 US stocks with expert analysis and actionable intelligence.
In other recent news, Harte Hanks Inc. reported significant developments from its 2025 Annual Meeting of Stockholders, as detailed in a recent SEC filing. Shareholders elected four nominees to the board of directors, with Genni Combes, John H. Griffin, Jr., Bradley Radoff, and Elizabeth Ross set to serve until the 2026 annual meeting. The company’s executive compensation package received approval on an advisory basis, indicating shareholder satisfaction with the pay structure. Additionally, stockholders ratified Wolf & Company P.C. as the independent registered public accounting firm for the fiscal year ending December 31, 2025. In another development, Harte Hanks entered a cooperation agreement with major shareholders Gary S. Rosenbach and Susan Rosenbach. The agreement includes standstill provisions and mutual non-disparagement clauses, with the Rosenbachs agreeing to vote in line with the Board’s recommendations. This agreement will remain effective until the Rosenbachs’ ownership drops below 10% of the company’s common stock. These recent developments reflect Harte Hanks’ ongoing corporate governance efforts and shareholder engagement strategies.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.